Shanghai Henlius Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
4,082
- Stock Symbol
-
02696
- Investments
-
1
- Share Price
-
$5.49
- (As of Friday Closing)
Shanghai Henlius General Information
Description
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Contact Information
Website
www.henlius.comCorporate Office
- 11th Floor, Building B8, Huaxin Huixiang City
- Number 188 Yizhou Road, Xuhui District
- Shanghai, 200233
- China
Corporate Office
- 11th Floor, Building B8, Huaxin Huixiang City
- Number 188 Yizhou Road, Xuhui District
- Shanghai, 200233
- China
Shanghai Henlius Stock Performance
As of 20-Nov-2026, Shanghai Henlius’s stock price is $5.49. Its current market cap is $2.99B with 545M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.49 | $5.64 | $5.36 - $11.12 | $2.99B | 545M | 971K | $0.23 |
Shanghai Henlius Financials Summary
As of 30-Jun-2026, Shanghai Henlius has a trailing 12-month revenue of $1.06B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,878,602 | 4,365,228 | 2,130,327 | 1,427,698 |
| Revenue | 1,062,589 | 927,038 | 797,781 | 762,544 |
| EBITDA | 197,692 | 184,227 | 184,220 | 145,756 |
| Net Income | 123,954 | 115,006 | 114,344 | 77,177 |
| Total Assets | 1,927,532 | 1,766,703 | 1,451,695 | 1,397,112 |
| Total Debt | 581,186 | 514,103 | 499,745 | 577,413 |
Shanghai Henlius Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shanghai Henlius Comparisons
Industry
Financing
Details
Shanghai Henlius Competitors (16)
One of Shanghai Henlius’s 16 competitors is Abbisko Medicine, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abbisko Medicine | Formerly VC-backed | Shanghai, China | ||||
| CARsgen Therapeutics | Formerly VC-backed | Shanghai, China | ||||
| EMD Serono | Corporation | Boston, MA | ||||
| Teva Pharmaceutical Industries | Corporation | Tel Aviv, Israel | ||||
| Innovent Biologics | Formerly VC-backed | Suzhou, China |
Shanghai Henlius Patents
Shanghai Henlius Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026219178-A1 | Pharmaceutical composition and use thereof | Pending | 14-Apr-2025 | ||
| WO-2026214567-A1 | Sialidase-b7h3-antibody conjugates and methods of using the same | Pending | 08-Apr-2025 | ||
| WO-2026209027-A1 | Anti-her2 antibody pharmaceutical formulation | Pending | 03-Apr-2025 | ||
| WO-2026145631-A1 | Ligand-drug conjugate, preparation method therefor and use thereof | Pending | 31-Dec-2024 | ||
| WO-2026130566-A1 | Ligand-drug conjugate, preparation method therefor and use thereof | Pending | 20-Dec-2024 |
Shanghai Henlius Signals
Shanghai Henlius Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Shanghai Henlius Investments (1)
Shanghai Henlius’s most recent deal was a Joint Venture with Joint Venture (Shanghai Helius / SVAX). The deal was made on 07-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Joint Venture (Shanghai Helius / SVAX) | 07-Nov-2024 | Joint Venture | Pharmaceuticals |
Shanghai Henlius ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.45 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Shanghai Henlius FAQs
-
When was Shanghai Henlius founded?
Shanghai Henlius was founded in 2009.
-
Where is Shanghai Henlius headquartered?
Shanghai Henlius is headquartered in Shanghai, China.
-
What is the size of Shanghai Henlius?
Shanghai Henlius has 4,082 total employees.
-
What industry is Shanghai Henlius in?
Shanghai Henlius’s primary industry is Drug Discovery.
-
Is Shanghai Henlius a private or public company?
Shanghai Henlius is a Public company.
-
What is Shanghai Henlius’s stock symbol?
The ticker symbol for Shanghai Henlius is 02696.
-
What is the current stock price of Shanghai Henlius?
As of 20-Nov-2026 the stock price of Shanghai Henlius is $5.49.
-
What is the current market cap of Shanghai Henlius?
The current market capitalization of Shanghai Henlius is $2.99B.
-
What is Shanghai Henlius’s current revenue?
The trailing twelve month revenue for Shanghai Henlius is $1.06B.
-
Who are Shanghai Henlius’s competitors?
Abbisko Medicine, CARsgen Therapeutics, EMD Serono, Teva Pharmaceutical Industries, and Innovent Biologics are some of the 16 competitors of Shanghai Henlius.
-
What is Shanghai Henlius’s annual earnings per share (EPS)?
Shanghai Henlius’s EPS for 12 months was $0.23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process